3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
20
Leukemia, Myeloid, Acute
8
Recurrence
7
Neoplasms, Plasma Cell
4
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma
3
Thymoma
2
Ovarian Neoplasms
2
Carcinoma
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Richter's Transformation
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Melanoma
1
MDS
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Cisplatin
68
Paclitaxel
32
Radiotherapy
31
Carboplatin
23
Bevacizumab
21
pembrolizumab
20
Brachytherapy
18
atezolizumab
11
camrelizumab
10
Nivolumab
10
Gemcitabine
10
Drug Therapy
9
tislelizumab
8
Topotecan
8
Taxes
8
Chemoradiotherapy
8
Radiation
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
zimberelimab
6
toripalimab
6
nimotuzumab
6
Magnetic Resonance Spectroscopy
6
Cetuximab
6
lenvatinib
5
durvalumab
5
dostarlimab
5
Platinum
5
Papillomavirus Vaccines
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Uterine Cervical Neoplasms
×
selinexor
×
Clear all
NCT02025985
2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2
Completed
116 enrolled
21 charts